Serum Immunoglobulin G Is a Marker of Hidradenitis Suppurativa Disease Severity

Hidradenitis suppurativa (HS) is a chronic inflammatory condition of the skin that is brought about by autoinflammation and hyperkeratosis at the pilosebaceous unit. The clinical severity of HS can be measured using static (Hurley Severity Scoring (HSS)) and/or dynamic (International HS Severity Sco...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2022-11, Vol.23 (22), p.13800
Main Authors: Mintoff, Dillon, Borg, Isabella, Pace, Nikolai P
Format: Article
Language:English
Subjects:
Biomarkers
C-reactive protein
Cross-Sectional Studies
Dermatology
Erythrocyte sedimentation rate
Erythrocytes
Gender
Hematology
Hidradenitis Suppurativa - diagnosis
Humans
IgG antibody
Immunoglobulin G
Immunoglobulins
Inflammation
Leukocytes (neutrophilic)
Lymphocytes
Metabolic syndrome
Pathophysiology
Plasma
Serology
Severity of Illness Index
Skin
Tumor necrosis factor-TNF
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hidradenitis suppurativa (HS) is a chronic inflammatory condition of the skin that is brought about by autoinflammation and hyperkeratosis at the pilosebaceous unit. The clinical severity of HS can be measured using static (Hurley Severity Scoring (HSS)) and/or dynamic (International HS Severity Scoring System (IHS4)) severity scoring instruments. However, few clinically available serological parameters have been found to correlate with disease severity. In this study, we sought to investigate the role of serum immunoglobulin (Ig) G, M and A levels as biomarkers of disease severity and to compare them with other, more conventional inflammatory indices, such as the erythrocyte sedimentation rate, C-reactive protein, the neutrophil-lymphocyte ratio, the platelet-lymphocyte ratio and the systemic immune-inflammation index. In this cross-sectional study, patients were recruited from the only dermatology referral centre in Malta, Europe, and subjected to clinical examination and the assessment of inflammatory and immunologic parameters. Serum IgG, M and A levels were assessed using the Atellica NEPH 630 System (SIEMENS-Healthineers AF, Erlangen, Germany) nephelometric analyser. Serum IgG, M and A levels correlate with both dynamic and static HS severity scoring systems. Serum IgG behaves as a marker of severe HS disease as categorised by HSS and the IHS4. Our findings suggest that the serum IgG level can be used in the clinical setting as a biomarker of disease severity and, therefore, as an adjunct to clinical severity scoring.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms232213800